Whats new
Whats new.
Maxim - P3 Study for Efti + Keytruda in 1L NSCLC Doses First Patient - Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)
March 25th 2025
For a copy of this analyst report please contact your Maxim advisor
Whats new
March 25th 2025
For a copy of this analyst report please contact your Maxim advisor